BioPharma Dive14d
Versant invests again in obesity, this time backing Helicore Biopharma
Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant in recent months.
Business Insider14d
Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions
By targeting GIP directly, we’ve rapidly advanced a differentiated ... Helicore’s R&D activities are supported by world-class protein engineering capabilities at Ridgeline, Versant’s discovery engine ...
Business Wire28d
Olfactive Biosolutions Granted Third Dual GLP-1 / GIP Patent to Repurpose Food Molecules for Weight Management and Blood Sugar Regulation
These ectopic receptors influence GLP-1 and GIP secretion, serotonin and dopamine ... The Olfactive Biosolutions team has deep expertise in receptor protein science and the food & beverage industry.
Morningstar14d
Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions
By targeting GIP directly, we’ve rapidly advanced a ... Helicore’s R&D activities are supported by world-class protein engineering capabilities at Ridgeline, Versant’s discovery engine ...